The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Oct. 04, 2019
Applicant:

International Institute of Cancer Immunology, Inc., Suita, JP;

Inventor:

Haruo Sugiyama, Minoo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/15 (2025.01); A61K 35/17 (2025.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); C12N 5/0784 (2010.01);
U.S. Cl.
CPC ...
A61K 39/001153 (2018.08); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01); C12N 5/0639 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55566 (2013.01); C12N 2501/415 (2013.01);
Abstract

The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1killer peptide and/or WT1helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.


Find Patent Forward Citations

Loading…